Education
About Us
Working with TipRanks
Follow Us
Kaken Pharmaceutical Co Ltd (KKPCF)
OTHER OTC:KKPCF
Total Valuation
Kaken Pharmaceutical Co has a market cap or net worth of $1.10B. The enterprise value is $95.02B.
Market Cap$1.10B
Enterprise Value$95.02B
Share Statistics
Kaken Pharmaceutical Co has 45,939,728 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,939,728
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kaken Pharmaceutical Co’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.04%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.04%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee63.47M
Profits Per Employee7.07M
Employee Count1,135
Asset Turnover0.42
Inventory Turnover1.95
Valuation Ratios
The current PE Ratio of Kaken Pharmaceutical Co is 16.30. Kaken Pharmaceutical Co’s PEG ratio is 0.35.
PE Ratio16.30
PS Ratio1.99
PB Ratio0.91
Price to Fair Value0.91
Price to FCF319.11
Price to Operating Cash Flow50.77
PEG Ratio0.35
Income Statement
In the last 12 months, Kaken Pharmaceutical Co had revenue of 72.04B and earned 8.03B in profits. Earnings per share was 212.66.
Revenue72.04B
Gross Profit38.54B
Operating Income9.51B
Pretax Income9.80B
Net Income8.03B
EBITDA12.57B
Earnings Per Share (EPS)212.66
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Kaken Pharmaceutical Co pays an annual dividend of $0.532, resulting in a dividend yield of 4.69%
Dividend Per Share$0.532
Dividend Yield4.69%
Payout Ratio13.84%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.35
52-Week Price Change26.64%
50-Day Moving Average29.72
200-Day Moving Average27.17
Relative Strength Index (RSI)28.74
Average Volume (3m)33.00
Important Dates
Kaken Pharmaceutical Co upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 6, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Kaken Pharmaceutical Co as a current ratio of 5.62, with Debt / Equity ratio of 2.48%
Current Ratio5.62
Quick Ratio4.72
Debt to Market Cap0.03
Net Debt to EBITDA-3.72
Interest Coverage Ratio559.59
Taxes
In the past 12 months, Kaken Pharmaceutical Co has paid 1.77B in taxes.
Income Tax1.77B
Effective Tax Rate0.18
Enterprise Valuation
Kaken Pharmaceutical Co EV to EBITDA ratio is 6.69, with an EV/FCF ratio of 205.02.
EV to Sales1.17
EV to EBITDA6.69
EV to Free Cash Flow205.02
EV to Operating Cash Flow32.62
Balance Sheet
Kaken Pharmaceutical Co has $79.75B in cash and marketable securities with ¥8.64B in debt, giving a net cash position of -$75.90B billion.
Cash & Marketable Securities$79.75B
Total Debt¥8.64B
Net Cash-$75.90B
Net Cash Per Share-$1.65K
Tangible Book Value Per Share$3.61K
Margins
Gross margin is 62.00%, with operating margin of 13.20%, and net profit margin of 11.14%.
Gross Margin62.00%
Operating Margin13.20%
Pretax Margin13.60%
Net Profit Margin11.14%
EBITDA Margin17.45%
EBIT Margin13.62%
Analyst Forecast
The average price target for Kaken Pharmaceutical Co is $40.49, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$40.49
Price Target Upside50.46% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―